Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

Table 4 Susceptibility of ICU and non-ICU ward subsets of lower respiratory tract infection isolates of P. aeruginosa and Enterobacterales to C/T and comparator agents^a,b,c – SMART 2018–2019, United States

Species/ward type	n	% Susceptible										% MDR
Species/ward type	n	C/T	P/T	FEP	CAZ	CRO	ATM	MEM	IMI	LVX	AMK	% MDR
P. aeruginosa^d
ICU	495	96.0	72.3	78.0	76.6	NA	68.1	72.9	64.4	66.7	96.2	17.8
Non-ICU	583	96.7	79.4	83.0	82.9	NA	72.2	79.8	69.0	61.9	96.6	10.5
Enterobacterales^e
ICU	1005	91.3	87.4	89.4	83.2	80.5	83.3	97.5	87.5	81.7	99.0	13.0
Non-ICU	726	92.6	89.3	89.4	83.3	79.6	85.1	98.5	85.1	83.0	98.6	11.7
P. aeruginosa + Enterobacterales
ICU	1500	92.9	82.4	85.6	81.0	NA	78.3	89.4	79.9	76.7	98.1	14.6
Non-ICU	1309	94.4	84.9	86.6	83.1	NA	79.4	90.1	77.9	73.6	97.7	11.2

^a Abbreviations: C/T, ceftolozane/tazobactam; P/T, piperacillin/tazobactam; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; ATM, aztreonam; MEM, meropenem; IMI, impenem; LVX, levofloxacin; AMK, amikacin; NA, not available
^b Table does not show results for colistin because P. aeruginosa and Enterobacterales cannot be categorized as susceptible to colistin using CLSI M100 (2020) MIC breakpoint criteria
^c Statistically significant differences between ICU and non-ICU are shown in bold font
^d Of the 1237 isolates P. aeruginosa, 48 were from emergency rooms and 111 did not have a location provided and were excluded from this analysis
^e Of the 1938 isolates of Enterobacterales, 57 were from emergency rooms and 150 did not have a location provided and were excluded from this analysis

ISSN: 1471-2180